PYRIDOSTIGMINE BROMIDE solution

Страна: Соединенные Штаты

Язык: английский

Источник: NLM (National Library of Medicine)

Активный ингредиент:

PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - UNII:19QM69HH21)

Доступна с:

VistaPharm, LLC

Администрация маршрут:

ORAL

Тип рецепта:

PRESCRIPTION DRUG

Терапевтические показания :

Pyridostigmine Bromide Oral Solution is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

Обзор продуктов:

Pyridostigmine Bromide Oral Solution, USP is a raspberry-flavored liquid containing 60 mg of pyridostigmine bromide per 5 mL and 5% alcohol, and is available as NDC 66689-406-01: 5 mL Unit-Dose cups NDC 66689-406-10: Case containing 10 Unit-Dose cups each of 5 mL (66689-406-01), packaged in 1 tray of 10 Unit-Dose cups each. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature].

Статус Авторизация:

Abbreviated New Drug Application

Характеристики продукта

PYRIDOSTIGMINE BROMIDE- PYRIDOSTIGMINE BROMIDE SOLUTION
VISTAPHARM, LLC
----------
PYRIDOSTIGMINE BROMIDE ORAL SOLUTION, USP 60 MG/5 ML
VISTAPHARM, INC.
DESCRIPTION:
Pyridostigmine Bromide Oral Solution, USP is an orally active
cholinesterase inhibitor.
Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium
bromide
dimethylcarbamate. Its structural formula is:
Pyridostigmine Bromide Oral Solution, USP contains 60 mg
pyridostigmine bromide per 5
mL in a vehicle containing 5% alcohol, glycerin, lactic acid, sodium
benzoate, sorbitol
solution, sucrose, FD&C Red No. 40, FD&C Blue No. 1, raspberry flavor
and water.
ACTIONS:
Pyridostigmine Bromide Oral Solution inhibits the destruction of
acetylcholine by
cholinesterase and there by permits freer transmission of nerve
impulses across the
neuromuscular junction. Pyridostigmine is an analog of neostigmine
(Prostigmin™), but
differs from it in certain clinically significant respects; for
example, pyridostigmine is
characterized by a longer duration of action and fewer
gastrointestinal side effects.
INDICATION:
Pyridostigmine Bromide Oral Solution, USP is useful in the treatment
of myasthenia
gravis.
CONTRAINDICATIONS:
Pyridostigmine Bromide Oral Solution is contraindicated in mechanical
intestinal or
urinary obstruction, and particular caution should be used in its
administration to
patients with bronchial asthma. Care should be observed in the use of
atropine for
counteracting side effects, as discussed below.
WARNINGS:
Although failure of patients to show clinical improvement may reflect
underdosage, it
can also be indicative of overdosage. As is true of all cholinergic
drugs, overdosage of
Pyridostigmine Bromide Oral Solution may result in cholinergic crisis,
a state
characterized by increasing muscle weakness which, through involvement
of the
muscles of respiration, may lead to death. Myasthenic crisis due to an
increase in the
severity of the disease is also accompanied by extreme muscle
weakness, and thus may
be difficult to distinguish from cholinergi